New drugs in development.
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D002219:Carbamates; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007674:Kidney Diseases / Q000139:chemically induced; D061466:Lopinavir; D010078:Oxazines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use; D019562:Viral Load; D000099227:Abacavir
D000225:Adenine; D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D002219:Carbamates; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D015507:Drugs, Investigational; D005663:Furans; D017320:HIV Protease Inhibitors; D007093:Imidazoles; D061466:Lopinavir; D010078:Oxazines; D011725:Pyridines; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D000099227:Abacavir; C113604:S 1153; C095108:amprenavir; C098320:efavirenz